This content is for healthcare professionals outside of the UK

Decline

Leave Feedback
Leave Feedback
Lung Cancer Watch Time: 28 mins

touchMDT Precision targeting of MET in NSCLC: A multidisciplinary approach

A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

 Overview & Learning Objectives
Patient with NSCLC with MET aberration
  • Targeting METex14 skipping mutations: Patient identification through molecular analysis
    Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
    Play Arrow Watch Video

    Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of an 81-year-old patient with NSCLC, and highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.

    Time: 12:28
    Dr Le, Dr Argento, Prof. Stenzinger
    Play Arrow Watch Video
  • Managing METex14 skipping mutations: Clinical insights and strategies
    Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
    Play Arrow Watch Video

    Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss the case of an 81-year-old patient with NSCLC with METex14 skipping mutation, and provide practical insights on treatment selection and patient management.

    Time: 14:45
    Dr Le, Dr Cuellar, Ms McDonald
    Play Arrow Watch Video
  • COMING SOON: 14 NOV 24
    Metastatic challenges: Exploring MET amplification in refractory disease
    Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
    Play Arrow Watch Video

    COMING SOON: 14 NOV 24
    Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of a patient with EGFR-TKI refractory NSCLC, including how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.

    Time: 01:00
    Dr Le, Dr Argento, Prof. Stenzinger
    Play Arrow Watch Video
  • COMING SOON: 14 NOV 24
    Navigating resistance: MET-targeted treatment strategies for refractory NSCLC
    Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
    Play Arrow Watch Video

    COMING SOON: 14 NOV 24
    Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.

    Time: 01:00
    Dr Le, Dr Cuellar, Ms McDonald
    Play Arrow Watch Video

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Christine Argento
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Prof. Albrecht Stenzinger
University Hospital Heidelberg, Germany

Dr Le, Dr Argento and Prof. Stenzinger discuss the case of an 81-year-old patient with NSCLC, and they highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.

Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

How confident do you feel in identifying oncogene driver mutations in patients with NSCLC?

Submit your answer to see the results

Not confident
   
A little confident
   
Moderately confident
   
Very confident
   
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
Get the Audio Version
Targeting METex14 skipping mutations: Patient identification through molecular analysis
Time: 12:28
Dr Le, Dr Argento, Prof. Stenzinger

Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of an 81-year-old patient with NSCLC, and highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.

Watch Next
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner

Managing METex14 skipping mutations: Clinical insights and strategies

Watch Now

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Sandra Cuellar
University of Illinois at Chicago, Chicago, IL, USA
Ms Stephanie McDonald
Dana-Farber Cancer Institute, Boston, MA, USA

Dr Le, Dr Cuellar and Ms McDonald consider treatment options and optimal management of an 81-year-old patient with NSCLC bearing METex14 skipping mutations.

Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What is your main concern when treating a patient with NSCLC with METex14 skipping mutation?

Submit your answer to see the results

Treatment selection
   
Efficacy of MET TKIs
   
Side effects of MET TKIs
   
Impact of treatment on QoL
   
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
Get the Audio Version
Managing METex14 skipping mutations: Clinical insights and strategies
Time: 14:45
Dr Le, Dr Cuellar, Ms McDonald

Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss the case of an 81-year-old patient with NSCLC with METex14 skipping mutation, and provide practical insights on treatment selection and patient management.

Watch Next
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist

COMING SOON: 14 NOV 24
Metastatic challenges: Exploring MET amplification in refractory disease

Watch Now

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Christine Argento
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Prof. Albrecht Stenzinger
University Hospital Heidelberg, Germany

Dr Le, Dr Argento and Prof. Stenzinger consider the case of a patient with EGFR-mutant NSCLC whose disease progresses under EGFR-TKI therapy. They discuss how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.

Get the Audio Version
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
Get the Audio Version
COMING SOON: 14 NOV 24
Metastatic challenges: Exploring MET amplification in refractory disease
Time: 01:00
Dr Le, Dr Argento, Prof. Stenzinger

COMING SOON: 14 NOV 24
Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of a patient with EGFR-TKI refractory NSCLC, including how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.

Watch Next
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner

COMING SOON: 14 NOV 24
Navigating resistance: MET-targeted treatment strategies for refractory NSCLC

Watch Now

Expert Spotlight

Dr Xiuning Le
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Sandra Cuellar
University of Illinois, Chicago, IL, USA
Ms Stephanie McDonald
Dana-Farber Cancer Institute, Boston, MA, USA

Dr Le, Dr Cuellar and Ms McDonald consider treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.

Get the Audio Version
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
Get the Audio Version
COMING SOON: 14 NOV 24
Navigating resistance: MET-targeted treatment strategies for refractory NSCLC
Time: 01:00
Dr Le, Dr Cuellar, Ms McDonald

COMING SOON: 14 NOV 24
Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.

Watch Next
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist

Targeting METex14 skipping mutations: Patient identification through molecular analysis

Watch Now
Back To Top
Overview & Learning Objectives
Overview

In this activity, five experts from the multidisciplinary team discuss the management of patients with advanced non-small cell lung cancer (NSCLC) bearing MET alterations. They consider biomarker testing, treatment selection and long-term care of patients newly diagnosed with METex14-mutated NSCLC, and patients who develop resistance to EGFR-targeted therapy due to METamplification.

Target Audience

This activity has been designed to meet the educational needs of oncologists, respiratory specialists, pathologists, oncology nurse specialists and hospital pharmacists involved in the management of NSCLC.

Faculty

Dr Xiuning Le discloses: Advisory board or panel fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho, Teligene and Taiho. Consultancy fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Spectrum Pharmaceutics, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho and Teligene and Taiho. Grants/Research support from ArriVent, Boehringer Ingelheim, Dizal, Eli Lilly, EMD Serono, Janssen, Regeneron, Takeda, Teligene and ThermoFisher.

Dr Christine Argento discloses: Advisory board or panel fees from Biodesix. Consultancy fees from Biodesix, Boston Scientific, Cook Medical, Intuitive Surgical and Olympus Therapeutics.

Dr Sandra Cuellar discloses: Advisory board or panel fees from Pharmacosmos (relationship terminated). Speaker’s bureau fees from Genentech and Seagen.

Ms Stephanie McDonald discloses: Consultancy fees from Pfizer.

Prof. Albrecht Stenzinger discloses: Advisory board or panel fees from AGCT, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda and Thermo Fisher Scientific. Grants/research support from Bayer, BMS, Chugai and Incyte.

Content reviewer

Christy Thai, PharmD, BCPS and Alicia Canalejo, APRN have no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Contributors

Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

Date of original release: 16 October 2024.  Date of expiration: 16 October 2025.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognize the importance of identifying patients with MET alterations in NSCLC and choose the most appropriate strategy to detect specific gene alterations
  • Evaluate the evidence from completed or ongoing clinical trials on the use of MET inhibitors in selected patients with advanced NSCLC and implications for future practice
  • Apply clinical trial data on MET inhibitors in NSCLC, including adverse event management, using an holistic approach to patient care
Faculty & Disclosures
Dr Xiuning Le

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Xiuning Le is an associate professor in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center in Houston, TX, USA.read more

Dr Le received her MD from Peking Union Medical College in China and then obtained a PhD in genetics at Harvard Medical School in Massachusetts. Subsequently, she completed her internal medicine residency at the University of Massachusetts Medical Center and a Hematology/Oncology Fellowship at Beth Israel Deaconess Medical Center in Massachusetts. She joined MD Anderson Cancer Center as a faculty member in the Department of Thoracic Medical Oncology.

Dr Le’s clinical focus is on oncogene-driven lung cancers. She applies genomics expertise in her translational work to understand resistance mechanisms to targeted therapy and immunotherapy. She serves as a principal investigator for multiple trials focusing on EGFR-mutant or MET exon 14 skipping non-small cell lung cancer. Dr Le is a recipient of many prestigious awards, such as the Stand Up To Cancer (SU2C) V Scholar, American Society of Clinical Oncology (ASCO) Young Investigator and ASCO Career Development Awards.

Dr Xiuning Le discloses: Advisory board or panel fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho, Teligene and Taiho. Consultancy fees from Abbvie, Abion, Arrivent, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Spectrum Pharmaceutics, Novartis, Regeneron, Sensei Biotherapeutics, Spectrum Pharmaceutics, SystImmune, Taiho and Teligene and Taiho. Grants/Research support from ArriVent, Boehringer Ingelheim, Dizal, Eli Lilly, EMD Serono, Janssen, Regeneron, Takeda, Teligene and ThermoFisher.
Dr Christine Argento

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Christine Argento is an associate professor of medicine at The Johns Hopkins University in Baltimore, MD, USA, where she specializes in interventional pulmonology.read more

Dr Argento graduated from St. George’s University School of Medicine in Grenada, completed an internal medicine residency at the University of Medicine and Dentistry in New Jersey, a Pulmonary and Critical Care Fellowship at Yale University in Connecticut, and an additional fellowship in Interventional Pulmonology at Duke University, North Carolina.

Her main focus is on the diagnosis and palliation of patients with lung cancer and evaluation of pulmonary nodules and pleural disease. Her research involves new technologies that further the field of interventional pulmonology, increasing awareness of lung cancer and lung cancer screening, as well as disparities in lung cancer and procedural simulation education.

Dr Argento is vice president of the Association of Interventional Pulmonary Program Directors (AIPPD) and is a founding and board member of Women in Interventional Pulmonology (WiIP). She also holds leadership roles in national societies such as CHEST and the American Thoracic Society (ATS), as well as the American Association of Bronchial and Interventional Pulmonology (AABIP).

Dr Christine Argento discloses: Advisory board or panel fees from Biodesix. Consultancy fees from Biodesix, Boston Scientific, Cook Medical, Intuitive Surgical and Olympus Therapeutics.
Dr Sandra Cuellar

University of Illinois, Chicago, IL, USA

Sandra Cuellar is a clinical associate professor in the Department of Pharmacy at the University of Illinois at Chicago (UIC) College of Pharmacy and a clinical oncology pharmacist at the University of Illinois (UI) Health, both in Chicago, IL, USA. read more

She serves as the director of the oncology residency programme, member of the Data and Safety Monitoring Committee and co-chair of the Institutional Review Board at UI Health.

Dr Cuellar received her PharmD degree from the UIC College of Pharmacy, then completed a pharmacy practice residency at the University of Kentucky Chandler Medical Center in Kentucky, followed by a specialty oncology residency at MD Anderson Cancer Center in Texas.

Dr Cuellar is an editor-at-large for the Journal of Hematology Oncology Pharmacyand has served as an invited lecturer for national organizations including the Hematology/Oncology Pharmacy Association (HOPA), American Society of Health-System Pharmacists (ASHP), American College of Clinical Pharmacy (ACCP), Association of Community Cancer Centers (ACCC) and Academy of Managed Care Pharmacy (AMCP). Dr Cuellar was recently appointed a member of the ASHP Commission on Credentialing and she is the past chair of the Industry Relation Council for HOPA.

Dr Sandra Cuellar discloses: Advisory board or panel fees from Pharmacosmos (relationship terminated). Speaker’s bureau fees from Genentech and Seagen.
Ms Stephanie McDonald

Dana-Farber Cancer Institute, Boston, MA, USA

Stephanie McDonald is a nurse practitioner in the Thoracic Oncology Program at Dana-Farber Cancer Institute in Boston, MA, USA, with experience in medical oncology at Lahey Hospital and Medical Center in Massachusetts and the Genitourinary and Melanoma Program at Dartmouth-Hitchcock Medical Center in New Haven.read more

Ms McDonald’s clinical focus includes targeted therapies for lung cancer, managing immune checkpoint inhibitor toxicities, and improving chemotherapy education for patients and families.

Stephanie McDonald has presented at national and international conferences, and her work has been published in the Journal of Cancer Research and Clinical Oncology.

Ms Stephanie McDonald discloses: Consultancy fees from Pfizer
Prof. Albrecht Stenzinger

University Hospital Heidelberg, Germany

Albrecht Stenzinger is professor of molecular tumour pathology and vice chair of the Institute of Pathology (IPH), as well as the director of the Center for Molecular Pathology at the IPH, University Hospital Heidelberg, Germany.read more

Prof. Stenzinger completed his MD degree at the University of Giessen, Germany, his residency and fellowship training in pathology at the Charité University Hospital in Berlin and the University Hospital Heidelberg, Germany, and is a board-certified surgical pathologist, a molecular pathologist and senior consultant pathologist. He received postdoctoral training at the University of Heidelberg and at Massachusetts General Hospital/Harvard Medical School, USA. He has broad expertise in molecular pathology and works primarily in translational research and genetics of solid tumours, including lung cancer.

Prof. Albrecht Stenzinger discloses: Advisory board or panel fees from AGCT, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda and Thermo Fisher Scientific. Grants/research support from Bayer, BMS, Chugai and Incyte.
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
Download Slides
REGISTER NOW FOR FREE ACCESS TO:
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

This content is intended for healthcare professionals outside the UK.

Date of original release: 16 October 2024. Date of expiration: 16 October 2025.

This content is intended for healthcare professionals outside the UK. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchMDT on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72